Marketing: Page 2


  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai falls behind on Leqembi patient goal

    The Alzheimer’s drug was administered to a total of 2,000 U.S. patients as of Jan. 26, signaling to analysts that an earlier goal of 10,000 may take longer than expected to hit.

    By Feb. 6, 2024
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen quits Aduhelm, handing back rights to original developer

    The decision to discontinue the controversial drug closes a tumultuous three-year saga that brought significant upheaval to the company.

    By Jan. 31, 2024
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Commercialization

    New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

    By BioPharma Dive staff
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    FDA orders new cancer warnings for CAR-T therapies

    The agency later modified its warning for Gilead's Tecartus, tweaking the label's language to reflect the fact that none of T cell malignancies in question had occurred in Tecartus-treated patients.

    By Updated Jan. 24, 2024
  • Ajay Purohit, a Biogen employee, points to brain scans of people with Alzheimer's
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi

    At the J.P. Morgan Healthcare Conference Monday, company head Chris Viehbacher said insurance reimbursement is now ‘not an issue’ for treatment.

    By Jan. 8, 2024
  • A Lilly sign is seen on the side of a building viewed through pine trees
    Image attribution tooltip
    jetcityimage via Getty Images
    Image attribution tooltip

    Lilly launches online service for home delivery of weight loss drug

    The new program, dubbed LillyDirect, will help patients connect with telehealth providers and deliver medicines like the company’s obesity drug Zepbound.

    By Jan. 4, 2024
  • Highway at sunset
    Image attribution tooltip

    stock.adobe.com/LeveL4

    Image attribution tooltip
    Sponsored by Alexander Group

    Profitable growth is on the horizon

    A return to profitable growth is on the horizon—organizations that take advantage of the following key trends can thrive in 2024 and beyond.

    Dec. 11, 2023
  • CVS storefront
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    CVS overhauls how its retail pharmacies charge for prescription drugs

    Under the new model, CVS’ pharmacy network will price drugs based on the amount the company paid for them, plus a defined markup and additional pharmacist fee.

    By Rebecca Pifer • Dec. 5, 2023
  • The European Union flag.
    Image attribution tooltip
    artJazz via Getty Images
    Image attribution tooltip
    Obesity drugs

    European regulators want to know more about the risks of GLP-1 drugs

    The EMA's safety committee has more questions for makers of the in-demand therapies as it reviews whether the drugs are linked to the risk of suicidal thoughts. 

    By Dec. 1, 2023
  • A Cigna logo behind a construction fence.
    Image attribution tooltip

    Matt Slocum/AP

    Image attribution tooltip

    Cigna, Humana in talks to merge: WSJ

    The merger would have major effects for the makeup of the U.S. health insurance industry, and would almost certainly face a regulatory challenge.

    By Rebecca Pifer • Nov. 29, 2023
  • A building in front of a pond with the sign "Medtronic" on a stone wall.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic CEO downplays impact of obesity drugs on procedures, devices

    Surging demand for GLP-1 agonists has put medtech firms like Medtronic under pressure, even as they argue the hit to their businesses will be minimal.

    By Ricky Zipp • Nov. 21, 2023
  • A photograph of an infusion bag of Abecma, a cell therapy from Bristol Myers Squibb and 2seventy bio
    Image attribution tooltip
    Courtesy of Bristol Myers Squibb
    Image attribution tooltip

    Bristol Myers faces FDA delay on cancer cell therapy decision

    The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.

    By Nov. 20, 2023
  • Boxes of the diabetes drug Ozempic are seen on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    New AMA policies target GLP-1 coverage, corporate medicine

    The lobbying group urged broader health insurance coverage for treating obesity, including with GLP-1 agonists like Wegovy.

    By Susanna Vogel • Nov. 14, 2023
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Obesity drugs

    Wegovy study details revive debate over GLP-1 impact on devices

    Shares in several heart device makers, which have been battered over the perceived impact of obesity medicines, rose this week following AHA data on Novo’s therapy.

    By Susan Kelly • Nov. 13, 2023
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    nopparit via Getty Images
    Image attribution tooltip

    Biogen, Sage set price of postpartum depression pill at $15,900

    The price is below what some analysts had predicted and significantly less than $34,000 Sage initially set for its earlier postpartum infusion, Zulresso.

    By Nov. 7, 2023
  • Woman smiling at a child
    Image attribution tooltip
    Permission granted by Viatris
    Image attribution tooltip
    Sponsored by Viatris

    Transforming MS care to meet patient needs

    Developing holistic treatment approaches that address patient needs today and in the future.

    By Abhijit Barve, MD, PhD, MBA, Chief Medical Officer, Viatris • Nov. 6, 2023
  • Boxes of the diabetes drug Ozempic rest on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo, Lilly buoyed by fast-growing GLP-1 drug sales

    The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.

    By Nov. 2, 2023
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Obesity drugs

    The obesity drug effect: What medical device executives are saying

    Stock selloffs across the medical device sector have erased hundreds of billions of dollars in market value. But medtech executives argue GLP-1 drug demand will complement, not cannibalize, their sales. 

    By Susan Kelly • Nov. 2, 2023
  • A office building is seen with a sign reading "GlaxoSmithKline."
    Image attribution tooltip
    Leon Neal via Getty Images
    Image attribution tooltip
    RSV vaccines

    GSK outpaces Pfizer in RSV vaccine market

    Sales of GSK’s new RSV shot Arexvy were more than double what Pfizer reported for its rival product, suggesting substantial demand this fall.

    By Kristin Jensen • Nov. 1, 2023
  • Focused women working on her laptop at the kitchen table
    Image attribution tooltip

    Shutterstock.com/fizkes

    Image attribution tooltip
    Sponsored by Veeva

    5 things to look for in a marketing analytics partner

    Effective marketing measurement requires objectivity, connected data, transparency, a track record of innovation and a proven ability to execute.

    Oct. 23, 2023
  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Zorica Nastasic via Getty Images
    Image attribution tooltip

    Roche eye drug sales grow as Regeneron plays catch-up

    The Swiss pharma reported expanding U.S. market share for its new AMD drug Vabysmo as Regeneron tries to rebound from a now-resolved delay for its high-dose Eylea.

    By Oct. 19, 2023
  • A vial of Merck & Co.'s cancer drug Keytruda next to its box.
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Keytruda gains first approval for pre- and post-surgery use in lung cancer

    The Merck drug leads competitors Opdivo and Imfinzi into a new immunotherapy setting, which aims to improve outcomes following the surgical removal of tumors.

    By Oct. 17, 2023
  • Exterior of FDA headquarters
    Image attribution tooltip
    Courtesy of U.S. Food and Drug Administration
    Image attribution tooltip

    Pfizer wins FDA approval for its $7B colitis drug

    Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.

    By Oct. 13, 2023
  • Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip
    ALS drug development

    Amylyx’s ALS drug knocked back again in Europe

    Following a re-examination, the EMA again concluded that Albrioza — known as Relyvrio in the U.S. — should not be cleared for the European market.

    By Oct. 13, 2023
  • The HLTH logo on a massive screen at the entrance hall to the convention.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive
    Image attribution tooltip
    Obesity drugs

    GLP-1 drug demand leaves employers in a bind over coverage

    Employers face a difficult decision over whether to cover the popular weight loss therapies, which cost between $900 and $1,400 for a typical month’s supply at list price.

    By Rebecca Pifer • Oct. 13, 2023
  • An image of Apellis Pharmaceuticals' vision loss drug Syfovre
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals
    Image attribution tooltip

    Apellis sales numbers show steady demand for new eye drug, despite safety worries

    The company says Syfovre prescriptions accelerated again in August after a rocky summer of side effect probes.

    By Kristin Jensen • Oct. 5, 2023